Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

RET mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

Related tests:

Oncomine™ Dx Target Test (11)

Oncomine™ Dx Target Test (11)

RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
RET mutation	Thyroid Gland Anaplastic Carcinoma	RET mutation	Thyroid Gland Anaplastic Carcinoma	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET mutation	Non Small Cell Lung Cancer	RET mutation	Non Small Cell Lung Cancer	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	TPX-0046 Sensitive: C2 – Inclusion Criteria TPX-0046 Sensitive : C2	TPX-0046 Sensitive: C2 – Inclusion Criteria TPX-0046 Sensitive : C2
RET mutation	Non Small Cell Lung Cancer	RET mutation	Non Small Cell Lung Cancer	TPX-0046 Sensitive: C2 – Inclusion Criteria TPX-0046 Sensitive : C2	TPX-0046 Sensitive: C2 – Inclusion Criteria TPX-0046 Sensitive : C2
RET mutation	Non Small Cell Lung Cancer	RET mutation	Non Small Cell Lung Cancer	BOS-172738 Sensitive: C2 – Inclusion Criteria BOS-172738 Sensitive : C2	BOS-172738 Sensitive: C2 – Inclusion Criteria BOS-172738 Sensitive : C2
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	BOS-172738 Sensitive: C2 – Inclusion Criteria BOS-172738 Sensitive : C2	BOS-172738 Sensitive: C2 – Inclusion Criteria BOS-172738 Sensitive : C2
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	SY-5007 Sensitive: C2 – Inclusion Criteria SY-5007 Sensitive : C2	SY-5007 Sensitive: C2 – Inclusion Criteria SY-5007 Sensitive : C2
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	RET inhibitor Sensitive: C3 – Early Trials RET inhibitor Sensitive : C3	RET inhibitor Sensitive: C3 – Early Trials RET inhibitor Sensitive : C3
RET mutation	Non Small Cell Lung Cancer	RET mutation	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
RET mutation	Melanoma	RET mutation	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3